Adakveo Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Adakveo market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historical period can be attributed to several factors, including the increasing prevalence and high severity of the disease, a rise in sickle cell anemia cases, growing demand for crizanlizumab, an increase in diagnosed cases of sickle cell disease (SCD), and advancements in pharmaceutical innovations for SCD.

Growth during the market's forecast period is expected to be driven by the rising prevalence of sickle cell disease, a growing demand for effective treatment options, a shift toward online shopping, an increase in the production of cell-based therapies, and better access to healthcare. Key trends in the forecast period include technological advancements, the integration of AI in drug development and diagnostics, innovations in drug delivery systems, and the use of AI in clinical trials.

The increasing prevalence of sickle cell disease (SCD) is expected to drive the growth of the adakveo market. Sickle cell disease is a group of inherited blood disorders caused by the presence of abnormal hemoglobin, known as hemoglobin S, in red blood cells. The rise in SCD prevalence is linked to factors such as higher birth rates in malaria-endemic regions, genetic inheritance patterns, and improved medical care, which has extended the lifespan of individuals living with the condition. Adakveo helps SCD patients by reducing the frequency of vaso-occlusive crises - painful episodes caused by blood flow blockage in small vessels. Its mechanism of action inhibits the adhesion of sickle cells to blood vessel walls, improving blood flow and alleviating symptoms. For example, according to the Pennsylvania Bar Institute (PBI), approximately 7.74 million people had sickle cell disease globally in 2021, and the number of diagnosed newborns is expected to rise from 275,000 in 2021 to over 400,000 by 2050. This increasing prevalence is contributing to the growth of the adakveo market.

Rising healthcare expenditure is set to boost the growth of the adakveo market. Healthcare expenditure includes the financial investments made by governments, private insurers, and individuals to improve and expand medical services. As healthcare spending increases, more investment is directed toward innovative treatments for sickle cell disease, improving patient access to Adakveo, which helps reduce the burden of vaso-occlusive crises and enhances quality of life. For instance, the UK experienced a 5.6% growth in healthcare spending from 2022 to 2023, totaling approximately $317.63 billion. The rise in healthcare expenditure enables access to specialty treatments such as adakveo, thereby propelling the market's growth.

In June 2022, Novartis AG, a Swiss-based pharmaceutical company, partnered with the American Society of Hematology (ASH) to improve access to sickle cell disease treatments in Sub-Saharan Africa, a region with a high prevalence of SCD but limited healthcare resources. This collaboration aims to make effective treatments, including Adakveo, more accessible in underserved areas, thus supporting global efforts to address the needs of SCD patients and further driving the growth of the adakveo market.

The key company operating in the adakveo market is Novartis AG.

North America was the largest region in the adakveo market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in adakveo report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the adakveo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Adakveo is a prescription medication used to prevent vaso-occlusive crises in patients with sickle cell disease. It works by targeting P-selectin to reduce blood cell clumping and inflammation. Adakveo helps lower the frequency of painful vaso-occlusive crises in individuals with sickle cell disease.

The primary indications for adakveo include sickle cell disease (for both adults and pediatric patients) and the prevention of vaso-occlusive crises. Sickle cell disease is a group of inherited blood disorders characterized by abnormal hemoglobin, known as hemoglobin S. The drug is administered through various routes, including intravenous injection, infusion therapy, and oral administration. Distribution channels for Adakveo include hospital pharmacies, retail pharmacies, and online pharmacies, while end users include hospitals, clinics, ambulatory care settings, and home care.

The adakveo market research report is one of a series of new reports that provides adakveo market statistics, including adakveo industry global market size, regional shares, competitors with a adakveo market share, detailed adakveo market segments, market trends, and opportunities, and any further data you may need to thrive in the adakveo industry. This adakveo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The adakveo market consists of sales of infusion sets, vials, injectable crizanlizumab, needles, and syringes. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.